SCYNEXIS (SCYX)

[dabonenose]

With Claytrader posting will come his band of shorts to try and knock it lower.

The good thing is, it usually doesn't last to long. IMO

He usually posts when there is a move on volume in a lower priced stock.

[hmuney]

NCT03734991 Study updated today and completed early https://clinicaltrials.gov/ct2/show/NCT03734991

[ClayTrader]

* * $SCYX Video Chart 09-18-2019 * *

Link to Video - click here to watch the technical chart video

[whytestocks]

News: $SCYX SCYNEXIS Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phase 3 Study (VANISH 303) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)

JERSEY CITY, N.J. , Sept. 18, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced completion of the last-patient/last-visit in its Phase 3 VANISH...

Got this from SCYX - SCYNEXIS Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phase 3 Study (VANISH 303) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)

[hmuney]

Nevermind. That's for antibiotics rather than antifungal.

[hmuney]

Good for $SCYX if true, but not great in general:

""
Johnson & Johnson, Sanofi, Pfizer, AstraZeneca, Novartis, Otsuka and many others have all gutted their antibiotic development teams and moved those budgets elsewhere. This is despite a 2016 pledge signed by over 100 companies, including Johnson & Johnson and Novartis, saying they would help prevent the next epidemic by investing in ways to combat the rise of antibiotic-resistant "superbugs."
""

https://www.dw.com/en/big-pharma-nixes-new-drugs-despite-impending-antibiotic-apocalypse/a-50432213

[hmuney]

Interesting read https://medicalxpress.com/news/2019-09-candida-auris-infection-patient-york.amp

[hmuney]

NCT03059992 Primary Completion Date: September 2019 https://clinicaltrials.gov/ct2/show/NCT03059992

[dabonenose]

SCYNEXIS, Inc. to Participate in Two Upcoming Investor Conferences
BY PR Newswire
— 7:00 AM ET 09/04/2019
JERSEY CITY, N.J., Sept. 4, 2019 /PRNewswire/ -- SCYNEXIS, Inc. ( SCYX ) , a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present in the following investor conferences:

The H.C. Wainwright Global Investment Conference at the Lotte New York Palace Hotel in New York City on Monday, September 9, 2019 at 2:10 p.m. ET.
The Ladenburg Thalmann Healthcare Conference at the Sofitel New York in New York City on Tuesday, September 24, 2019 at 1:30 p.m. ET.
Live webcasts of the presentations will be available on the Investors section of the Company's website: www.scynexis.com. Replays of the presentations will be available approximately two hours after each event and will be available for two weeks following each presentation.

[hmuney]

https://www.scynexis.com/news-media/press-releases/detail/186/scynexis-reports-second-quarter-2019-financial-results-and

[hmuney]

Update to NCT03987620 posted 8/6. Looks like they added locations and contacts. https://clinicaltrials.gov/ct2/history/NCT03987620?A=2&B=3&C=merged#StudyPageTop

[hmuney]

https://academic.oup.com/jac/advance-article-abstract/doi/10.1093/jac/dkz277/5532212

https://seekingalpha.com/instablog/6496881-bhavneesh-sharma/5327581-key-takeaways-follow-phone-call-scynexis-ceo

[hmuney]

CDC case count updated on their website on July 12th (as of May 31st):

https://www.cdc.gov/fungal/candida-auris/index.html

[hmuney]

Looks like there's something to slow the spread of Candida auris.

https://www.prnewswire.com/news-releases/new-fda-cleared-microbicidal-liquid-kills-deadly-drug-resistant-candida-auris-superbug-on-contact-300882814.html

[hmuney]

Mentions $SCYX https://academic.oup.com/mmy/article/57/Supplement_3/S328/5530955

[hmuney]

https://www.federalregister.gov/documents/2019/04/02/2019-06390/limited-population-pathway-for-antibacterial-and-antifungal-drugs-public-meeting-request-for

https://www.eventbrite.com/e/limited-population-pathway-for-antibacterial-and-antifungal-drugs-lpad-public-meeting-tickets-54015228001

[hmuney]

[hmuney]

Hopefully there is something to look forward to this Friday (7/12).

"Additionally, Taglietti is looking forward to an FDA meeting on July 12 in Washington. Following the passage of the limited population pathway for antibacterial and antifungal drugs — established by the 21st Century Cures Act — the FDA can now grant approval for some anti-infective products on the basis of limited clinical data." (Source: https://njbiz.com/hope-on-the-hudson/)

[whytestocks]

News: $SCYX SCYNEXIS to Present Data at ASM Microbe 2019 Demonstrating the Broad Potential Utility of Ibrexafungerp for the Treatment and Prevention of Multiple Severe Fungal Infections

JERSEY CITY, N.J. , June 5, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that a total of nine presentations revealing data which further d...

Read the whole news https://marketwirenews.com/news-releases/scynexis-to-present-data-at-asm-microbe-2019-demonstrating-the-broad-potential-utility-of-ibrexafungerp-for-the-treatment-and-prevention-of-multiple-severe-fungal-infections-8303204.html

[playofthedivine]

A little more drop and I'll accumulate a few thousand more shares. Only additional perceived positive news will pop this back to $1.80 and on towards $2. Patience pays like with PRED.

[dabonenose]

Better late, than never amigo.

[quito_yume]

This looks like the place to be. I'm gonna start accumulating this. Hello everyone and glta

[playofthedivine]

Can we get a dragonfly Doji to signify a bullish up trend?

[dabonenose]

My averages in three accouns is 1.29, .75 and 1.30.

[playofthedivine]

Yep! Love the gap fill. So far anyway. my first positions filled today at 1.73 & 1.61

[dabonenose]

1.60-1.63 looks like good support to pick some up. If that breaks, then 1.40 area IMO.

http://tos.mx/6tBZ64

These T or S charts dont translate right. my targs are good

[dabonenose]

JSB, well the shorts are protecting their positions this morning so far.

[jsb330]

We should see great movement Monday. https://www.contagionlive.com/news/furi-study-case-ibrexafungerp-successfully-treats-esophageal-candidiasis

[playofthedivine]

Bone:
Actually finding way better deep research at Seeking Alpha.
Scynexis, Undervalued And Filling A Critical Need In The Antifungal Space - George Crist
But you have to be a premium member to read the article. I was able to read all the comments of this article via the StockTwits link I discovered.

Cheers
Michael

[playofthedivine]

Thanks mate! Starting to do a little research now. Thinking we might see a dip here as it’s in overbought territory.

I tend to avoid StockTwits because of all of the noise. Too many Yahoos to sort through. But I’ll check it out anyway to see if I can find the members you’re referring to

[playofthedivine]

Thanks mate! Will follow up with some reading this weekend

[dabonenose]

Play,,,theres some decent DD posters over here bud. You gotta wade through some crap to get it(one line posters, etc.), but it's worth the trip IMO.

Find some posters with DR/MD in their monikers(doctors).

https://stocktwits.com/symbol/SCYX

[playofthedivine]

One helluva chart this one has. Have to do some due diligence now. Has anyone gathered some due diligence in terms of management and numbers they care to share on this board ? Not that I’m lazy, but sometimes some members here have done some extensive DD that they’re willing to share

[whytestocks]

News: $SCYX SCYNEXIS Commends the New York Times for its Reporting on Candida auris and Other Drug-Resistant Pathogens

JERSEY CITY, N.J. , April 8, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today commended the New York Times for its reporting   on Candida auris and the ...

Got this from https://marketwirenews.com/news-releases/scynexis-commends-the-new-york-times-for-its-reporting-on-candida-auris-and-other-drug-resistant-pathogens-7963102.html

[Alyssa]

$1.85 in premarket - up 13.5%.

[bosman]

This is a buy at this point with the little DD i did do, 5.00+ near future am i right or what. Watching close.

[axelvento]

Superbugs and Superdrugs March 2019 presentation https://d1io3yog0oux5.cloudfront.net/_bd344b25629c2fa2f8a9e4ceca4bb57d/scynexis/db/385/2887/pdf/PRESENTATION_IBX+Pneumocystis_Superbugs+and+Superdrugs_Final.pdf

less than three
weeks for furi & cares data at ECCMID


https://www.eccmid.org/


LONG$$$$$$$

[dabonenose]

I hear ya. It's starting to wake up and I beloieve the value is starting to be noticed.

They reported good numbers and with the accum that happened on Thursday, I think we may get some upgrades.

The houses always accum first, then put out their upgrades to reward their people.

Of course all IMHO,,,lol.

[wesley_]

agreed!

[whytestocks]

News: $SCYX SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update

JERSEY CITY, N.J. , March 14, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the year ended December 31, 2018 , and provide...

Read the whole news https://marketwirenews.com/news-releases/scynexis-reports-full-year-2018-financial-results-and-provides-company-update-7848416.html

[Alyssa]

Great day for SCYX. Can you believe the share price was in the $.30's and $.40's at the end of December? So ridiculously undervalued.

[wesley_]

$1.50 nice, loaded some

[axelvento]

nice$

[Heel Hulk]

8-k our today:

Item 8.01. Other Events

On February 14, 2019, SCYNEXIS received a letter from the Listing Qualifications Department staff (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying SCYNEXIS that, for the last 10 consecutive business days, the closing bid price for SCYNEXIS’s common stock has been equal to or in excess of the $1.00 per share minimum bid price requirement for continued listing, as required by Listing Rule 5450(a)(1). Accordingly, the Staff of Nasdaq has determined that SCYNEXIS has regained compliance with Nasdaq Listing Rule 5450(a)(1) and the matter is closed.

[axelvento]

https://fintel.io/so/us/scyx

[fabius]

If they decide to go for a commercial partnership, when announced it could reprice dramatically.

It is still very low compared to 18months ago

[Heel Hulk]

Love this steady climber with significant FDA catalysts ahead. Hoping for more presentations in the interim so I can wrap more of my simple brain around the science.

[dabonenose]

EL,,,lol, you're just on the wrong board!

[axelvento]

next catalyst>> The CARES study, evaluating oral ibrexafungerp for the treatment of patients with Candida auris infections, is ongoing with several patients enrolled. C. auris is an emerging life-threatening and multidrug-resistant fungal pathogen, with a mortality rate of up to 60%. CARES is the first study assessing an investigational agent against this pathogen.


https://www.scynexis.com/pipeline/invasive-candidiasis

https://clinicaltrials.gov/ct2/show/NCT03363841?term=CARES+%2B+SCYNEXIS&rank=1





february 2019

[El Trin]

Buy time?